CAS CAS Pharmacology & Medication-Assisted Treatment 2 — Questions and Answers
Question 1: Under the DATA 2000 waiver (now updated by the SUPPORT Act), which providers were originally authorized to prescribe buprenorphine for OUD in office-based settings?
- Pharmacists with board certification in addiction
- Physicians who obtained a DEA X-waiver after completing required training (Correct answer)
- Any healthcare provider with a DEA registration
- Only addiction medicine specialists at OTPs
Correct answer: Physicians who obtained a DEA X-waiver after completing required training
DATA 2000 established the DEA X-waiver system allowing qualifying physicians to prescribe buprenorphine for OUD after completing required training hours, later expanded to nurse practitioners and physician assistants.
Question 2: Medication-Assisted Treatment (MAT) is best defined as the use of FDA-approved medications combined with:
- Inpatient detoxification only
- Counseling and behavioral therapies to provide a whole-patient approach (Correct answer)
- Pharmaceutical management without psychosocial support
- Mandatory 12-step program participation
Correct answer: Counseling and behavioral therapies to provide a whole-patient approach
SAMHSA defines MAT as a combination of FDA-approved medications with counseling and behavioral therapies, recognizing that medication alone is insufficient for long-term recovery.
Question 3: A client on methadone maintenance asks why they cannot receive take-home doses after one week. The CAS should explain that take-home doses are granted based on:
- Insurance approval timelines
- Federal regulations that require demonstrated stability and time in treatment before take-home privileges are granted (Correct answer)
- The prescribing physician's personal preference
- The client's self-reported sobriety
Correct answer: Federal regulations that require demonstrated stability and time in treatment before take-home privileges are granted
Federal regulations (42 CFR Part 8) establish specific criteria—including time in treatment, urine drug screen results, and behavioral stability—that must be met before take-home doses are permitted.
Question 4: Opioid-induced precipitated withdrawal can occur when buprenorphine is administered while full opioid agonists are still occupying receptors because:
- Buprenorphine accelerates opioid metabolism in the liver
- Buprenorphine displaces full agonists from receptors but only partially activates them, causing abrupt withdrawal (Correct answer)
- Buprenorphine blocks dopamine release entirely
- Buprenorphine increases the dose of opioids required for effect
Correct answer: Buprenorphine displaces full agonists from receptors but only partially activates them, causing abrupt withdrawal
Because buprenorphine has high receptor affinity, it displaces full agonists but produces only partial activation, causing sudden, severe withdrawal if given too soon after the last full agonist dose.
Question 5: Which of the following is a primary advantage of extended-release injectable naltrexone (Vivitrol) over oral naltrexone for OUD?
- It can be self-administered at home daily
- It eliminates adherence problems associated with daily oral dosing (Correct answer)
- It provides partial opioid agonist activity to reduce withdrawal
- It is less expensive and more widely available
Correct answer: It eliminates adherence problems associated with daily oral dosing
Extended-release injectable naltrexone is administered monthly by a clinician, eliminating the daily adherence challenge that frequently leads to oral naltrexone discontinuation.
Question 6: When counseling a client prescribed MAT, the CAS should address common stigma by explaining that MAT medications are:
- A temporary crutch that should be discontinued as soon as possible
- Evidence-based treatments that reduce mortality, decrease illicit drug use, and support sustained recovery (Correct answer)
- Only appropriate for clients who have failed all other treatments
- A substitute addiction that prolongs dependence
Correct answer: Evidence-based treatments that reduce mortality, decrease illicit drug use, and support sustained recovery
Robust evidence shows that MAT reduces overdose deaths, decreases illicit opioid use, lowers criminal activity, and improves treatment retention—providing a foundation for stable, long-term recovery.
CAS CAS Pharmacology & Medication-Assisted Treatment 2
Under the DATA 2000 waiver (now updated by the SUPPORT Act), which providers were originally authorized to prescribe buprenorphine for OUD in office-based settings?